Jermasek Douglas has filed 10 insider transactions across 1 company since March 2023.
Most recent transaction: a grant/award of 10000 shares of Unicycive Therapeutics, Inc. ($UNCY) on July 28, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| July 28, 2025 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 10000 | $0.00 | 215,500.0000 | 12,302,059 | 4.87% | 0.08% |
| Aug. 12, 2024 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 81750 | $0.00 | 2,055,000.0000 | 9,405,285 | 4.14% | 0.87% |
| April 15, 2024 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 463250 | $0.00 | 1,973,250.0000 | 34,912,692 | 30.68% | 1.33% |
| Aug. 28, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 1355000 | $0.00 | 1,510,000.0000 | 15,234,570 | 874.19% | 8.89% |
| July 11, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | M | Common Stock | 104612 | $0.00 | 175,012.0000 | 15,234,570 | 148.60% | 0.69% |
| July 11, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | M | Series A-1 Convertible Preferred Stock | 50 | $1000.00 | 0.0000 | 15,234,570 | 100.00% | 0.00% |
| July 11, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy | 79252 | $0.00 | 79,252.0000 | 15,234,570 | 9999.99% | 0.52% |
| July 11, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy) | 72047 | $0.00 | 72,047.0000 | 15,234,570 | 9999.99% | 0.47% |
| July 11, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy) | 115275 | $0.00 | 115,275.0000 | 15,234,570 | 9999.99% | 0.76% |
| March 8, 2023 | Unicycive Therapeutics, Inc. | $UNCY | Jermasek Douglas | EVP of Corporate Strategy | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 15,057,049 | 9999.99% | 0.00% |